RxDoctor Payments Data

Hena Arora

Psychiatric/Mental Health · Hattiesburg, MSNPI 1821742289

Payments from drug & device makers

$1,115in general payments, 2019–2025

Across 58 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$354
  • Johnson & Johnson$220
  • Neurocrine Biosciences, Inc.$154
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
  • Teva Pharmaceuticals USA, Inc.$82
  • Otsuka America Pharmaceutical, Inc.$66
  • plus $129 from 4 others

What the payments were for

  • Food & beverage$1,115100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,115 in reported general payments places this provider in the 60th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$11,391
Medicare patients
99
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate284$870,916
Abilify MaintenaAripiprazole94$250,248
Invega TrinzaPaliperidone Palmitate17$168,222
VraylarCariprazine Hcl107$145,048
RexultiBrexpiprazole47$67,940
AustedoDeutetrabenazine14$64,720
AristadaAripiprazole Lauroxil29$62,965
TrintellixVortioxetine Hydrobromide66$45,684
LybalviOlanzapine/Samidorphan Malate22$33,216
Paliperidone ErPaliperidone59$18,993
FanaptIloperidone11$11,382
Clozapine99$8,521
Divalproex Sodium ErDivalproex Sodium122$5,377
Aripiprazole192$4,603
Haloperidol Decanoate68$3,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$220$1,039,137301 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$66$318,188141 claims
AbbVieVraylar$62$145,048107 claims
Alkermes, Inc.Aristada, Lybalvi$354$96,18151 claims
Teva Pharmaceuticals USA, Inc.Austedo$82$64,72014 claims
Vanda Pharmaceuticals Inc.Fanapt$25$11,38211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →